Chromodomain antagonists that target the polycomb-group methyllysine reader protein chromobox homolog 7 (CBX7)

Journal of Medicinal Chemistry

Volumn 57, Issue 7, 2014, Pages 2874-2883

  Simhadri, Chakravarthi ^a   Daze, Kevin D ^a   Douglas, Sarah F ^a   Quon, Taylor T H ^a   Dev, Amarjot ^a   Gignac, Michael C ^a   Peng, Fangni ^a   Heller, Markus ^b   Boulanger, Martin J ^a   Wulff, Jeremy E ^a   Hof, Fraser ^a  

^a UNIVERSITY OF VICTORIA   (Canada)

^b Centre for Drug Research and Development   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHROMOBOX HOMOLOG 7; FALKME3S ANALOG; HISTONE H3; LYSINE; POLYCOMB GROUP PROTEIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; DRUG POTENCY; FLUORESCENCE POLARIZATION; HUMAN; ISOTHERMAL TITRATION CALORIMETRY; LIGAND BINDING; MOLECULAR RECOGNITION; MULTIPLE CANCER; PROTEIN BINDING; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

CHROMOSOMAL PROTEINS, NON-HISTONE; CRYSTALLOGRAPHY, X-RAY; FLUORESCENCE POLARIZATION; HISTONES; HUMANS; LYSINE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PEPTIDE FRAGMENTS; POLYCOMB REPRESSIVE COMPLEX 1; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84898474268     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401487x     Document Type: Article

References (54)

1. Strahl, B. D.; Allis, C. D the language of covalent histone modifications Nature 2000, 403, 41-45
2. de la Cruz, X.; Lois, S.; Sanchez-Molina, S.; Martinez-Balbas, M. A. Do protein motifs read the histone code? BioEssays 2005, 27, 164-175
3. Migliori, V.; Muller, J.; Phalke, S.; Low, D.; Bezzi, M.; Mok, W. C.; Sahu, S. K.; Gunaratne, J.; Capasso, P.; Bassi, C.; Cecatiello, V.; De Marco, A.; Blackstock, W.; Kuznetsov, V.; Amati, B.; Mapelli, M.; Guccione, E. Symmetric dimethylation of H3R2 is a newly identified histone mark that supports euchromatin maintenance Nat. Struct. Mol. Biol. 2012, 19, 136-144
4. Taverna, S. D.; Li, H.; Ruthenburg, A. J.; Allis, C. D.; Patel, D. J. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers Nat. Struct. Mol. Biol. 2007, 14, 1025-1040
5. Daigle, S. R.; Olhava, E. J.; Therkelsen, C. A.; Basavapathruni, A.; Jin, L.; Boriack-Sjodin, P. A.; Allain, C. J.; Klaus, C. R.; Raimondi, A.; Scott, M. P.; Waters, N. J.; Chesworth, R.; Moyer, M. P.; Copeland, R. A.; Richon, V. M.; Pollock, R. M. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia Blood 2013, 122, 1017-1025
6. Anglin, J. L.; Song, Y. A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L J. Med. Chem. 2013, 56, 8972-8983
7. Takawa, M.; Masuda, K.; Kunizaki, M.; Daigo, Y.; Takagi, K.; Iwai, Y.; Cho, H.-S.; Toyokawa, G.; Yamane, Y.; Maejima, K.; Field, H. I.; Kobayashi, T.; Akasu, T.; Sugiyama, M.; Tsuchiya, E.; Atomi, Y.; Ponder, B. A. J.; Nakamura, Y.; Hamamoto, R. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker Cancer Sci. 2011, 102, 1298-1305
8. McCabe, M. T.; Ott, H. M.; Ganji, G.; Korenchuk, S.; Thompson, C.; Van Aller, G. S.; Liu, Y.; Graves, A. P.; Della Pietra, A., 3rd; Diaz, E.; LaFrance, L. V.; Mellinger, M.; Duquenne, C.; Tian, X.; Kruger, R. G.; McHugh, C. F.; Brandt, M.; Miller, W. H.; Dhanak, D.; Verma, S. K.; Tummino, P. J.; Creasy, C. L. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations Nature 2012, 492, 108-112
9. Verma, S. K.; Tian, X. R.; LaFrance, L. V.; Duquenne, C.; Suarez, D. P.; Newlander, K. A.; Romeril, S. P.; Burgess, J. L.; Grant, S. W.; Brackley, J. A.; Graves, A. P.; Scherzer, D. A.; Shu, A.; Thompson, C.; Ott, H. M.; Van Aller, G. S.; Machutta, C. A.; Diaz, E.; Jiang, Y.; Johnson, N. W.; Knight, S. D.; Kruger, R. G.; McCabe, M. T.; Dhanak, D.; Tummino, P. J.; Creasy, C. L.; Miller, W. H. Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2 ACS Med. Chem. Lett. 2012, 3, 1091-1096
10. Knutson, S. K.; Warholic, N. M.; Wigle, T. J.; Klaus, C. R.; Allain, C. J.; Raimondi, A.; Porter Scott, M.; Chesworth, R.; Moyer, M. P.; Copeland, R. A.; Richon, V. M.; Pollock, R. M.; Kuntz, K. W.; Keilhack, H. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 7922-7927
11. Wigle, T. J.; Copeland, R. A. Drugging the human methylome: an emerging modality for reversible control of aberrant gene transcription Curr. Opin. Chem. Biol. 2013, 17, 369-378
12. Yao, Y.; Chen, P.; Diao, J.; Cheng, G.; Deng, L.; Anglin, J. L.; Prasad, B. V.; Song, Y. Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies J. Am. Chem. Soc. 2011, 133, 16746-16749
13. Marks, P. A. Discovery and development of SAHA as an anticancer agent Oncogene 2007, 26, 1351-1356
14. Stimson, L.; Wood, V.; Khan, O.; Fotheringham, S.; La Thangue, N. B. HDAC inhibitor-based therapies and haematological malignancy Ann. Oncol. 2009, 20, 1293-1302
15. New, M.; Olzscha, H.; La Thangue, N. B. HDAC inhibitor-based therapies: Can we interpret the code? Mol. Oncol. 2012, 6, 637-656
16. Matzuk, M. M.; McKeown, M. R.; Filippakopoulos, P.; Li, Q.; Ma, L.; Agno, J. E.; Lemieux, M. E.; Picaud, S.; Yu, R. N.; Qi, J.; Knapp, S.; Bradner, J. E. Small-molecule inhibition of BRDT for male contraception Cell 2012, 150, 673-684
17. Banerjee, C.; Archin, N.; Michaels, D.; Belkina, A. C.; Denis, G. V.; Bradner, J.; Sebastiani, P.; Margolis, D. M.; Montano, M. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1 J. Leukocyte Biol. 2012, 92, 1147-1154
18. Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W. B.; Fedorov, O.; Morse, E. M.; Keates, T.; Hickman, T. T.; Felletar, I.; Philpott, M.; Munro, S.; McKeown, M. R.; Wang, Y.; Christie, A. L.; West, N.; Cameron, M. J.; Schwartz, B.; Heightman, T. D.; La Thangue, N.; French, C. A.; Wiest, O.; Kung, A. L.; Knapp, S.; Bradner, J. E. Selective inhibition of BET bromodomains Nature 2010, 468, 1067-1073
19. Loven, J.; Hoke, H. A.; Lin, C. Y.; Lau, A.; Orlando, D. A.; Vakoc, C. R.; Bradner, J. E.; Lee, T. I.; Young, R. A. Selective inhibition of tumor oncogenes by disruption of super-enhancers Cell 2013, 153, 320-334
20. Liu, L.; Zhen, X. T.; Denton, E.; Marsden, B. D.; Schapira, M. ChromoHub: a data hub for navigators of chromatin-mediated signalling Bioinformatics 2012, 28, 2205-2206
21. Yap, K. L.; Zhou, M. M. Structure and mechanisms of lysine methylation recognition by the chromodomain in gene transcription Biochemistry 2011, 50, 1966-1980
22. Santiago, C.; Nguyen, K.; Schapira, M. Druggability of methyl-lysine binding sites J. Comput.-Aided. Mol. Des. 2011, 25, 1171-1178
23. Kireev, D.; Wigle, T. J.; Norris-Drouin, J.; Herold, J. M.; Janzen, W. P.; Frye, S. V. Identification of non-peptide malignant brain tumor (MBT) repeat antagonists by virtual screening of commercially available compounds J. Med. Chem. 2010, 53, 7625-7631
24. Gao, C.; Herold, J. M.; Kireev, D.; Wigle, T.; Norris, J. L.; Frye, S. Biophysical probes reveal a "compromise" nature of the methyl-lysine binding pocket in L3MBTL1 J. Am. Chem. Soc. 2011, 133, 5357-5362
25. Herold, J. M.; Wigle, T. J.; Norris, J. L.; Lam, R.; Korboukh, V. K.; Gao, C.; Ingerman, L. A.; Kireev, D. B.; Senisterra, G.; Vedadi, M.; Tripathy, A.; Brown, P. J.; Arrowsmith, C. H.; Jin, J.; Janzen, W. P.; Frye, S. V. Small-molecule ligands of methyl-lysine binding proteins J. Med. Chem. 2011, 54, 2504-2511
26. James, L. I.; Korboukh, V. K.; Krichevsky, L.; Baughman, B. M.; Herold, J. M.; Norris, J. L.; Jin, J.; Kireev, D. B.; Janzen, W. P.; Arrowsmith, C. H.; Frye, S. V. Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3 J. Med. Chem. 2013, 56, 7358-7371
27. Camerino, M. A.; Zhong, N.; Dong, A.; Dickson, B.; James, L.; Baughman, B.; Norris, J.; Kireev, D.; Janzen, W. P.; Arrowsmith, C.; Frye, S. V the structure-activity relationships of L3MBTL3 inhibitors: a second series of potent compounds which bind the L3MBTL3 dimer MedChemComm 2013, 4, 1501-1507
28. James, L. I.; Barsyte-Lovejoy, D.; Zhong, N.; Krichevsky, L.; Korboukh, V. K.; Herold, J. M.; MacNevin, C. J.; Norris, J. L.; Sagum, C. A.; Tempel, W.; Marcon, E.; Guo, H. B.; Gao, C.; Huang, X. P.; Duan, S. L.; Emili, A.; Greenblatt, J. F.; Kireev, D. B.; Jin, J.; Janzen, W. P.; Brown, P. J.; Bedford, M. T.; Arrowsmith, C. H.; Frye, S. V. Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain Nat. Chem. Biol. 2013, 9, 184-191
29. Wagner, E. K.; Nath, N.; Flemming, R.; Feltenberger, J. B.; Denu, J. M. Identification and characterization of small molecule inhibitors of a plant homeodomain finger Biochemistry 2012, 51, 8293-8306
30. Eissenberg, J. C. Structural biology of the chromodomain: form and function Gene 2012, 496, 69-78
31. Kaustov, L.; Ouyang, H.; Amaya, M.; Lemak, A.; Nady, N.; Duan, S.; Wasney, G. A.; Li, Z.; Vedadi, M.; Schapira, M.; Min, J.; Arrowsmith, C. H. Recognition and specificity determinants of the human cbx chromodomains J. Biol. Chem. 2011, 286, 521-529
32. Blus, B. J.; Wiggins, K.; Khorasanizadeh, S. Epigenetic virtues of chromodomains Crit. Rev. Biochem. Mol. Biol. 2011, 46, 507-526
33. Gieni, R. S.; Hendzel, M. J. Polycomb group protein gene silencing, non-coding RNA, stem cells, and cancer Biochem. Cell Biol. 2009, 87, 711-746
34. Bracken, A. P.; Helin, K. Polycomb group proteins: navigators of lineage pathways led astray in cancer Nat. Rev. Cancer 2009, 9, 773-784
35. Sauvageau, M.; Sauvageau, G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer Cell Stem Cell 2010, 7, 299-313
36. Morey, L.; Pascual, G.; Cozzuto, L.; Roma, G.; Wutz, A.; Benitah, S. A.; Di Croce, L. Nonoverlapping functions of the Polycomb group Cbx family of proteins in embryonic stem cells Cell Stem Cell 2012, 10, 47-62
37. O'Loghlen, A.; Munoz-Cabello, A. M.; Gaspar-Maia, A.; Wu, H. A.; Banito, A.; Kunowska, N.; Racek, T.; Pemberton, H. N.; Beolchi, P.; Lavial, F.; Masui, O.; Vermeulen, M.; Carroll, T.; Graumann, J.; Heard, E.; Dillon, N.; Azuara, V.; Snijders, A. P.; Peters, G.; Bernstein, E.; Gil, J. MicroRNA regulation of Cbx7 mediates a switch of Polycomb orthologs during ESC differentiation Cell Stem Cell 2012, 10, 33-46
38. Gil, J.; Bernard, D.; Martinez, D.; Beach, D. Polycomb CBX7 has a unifying role in cellular lifespan Nat. Cell Biol. 2004, 6, 67-72
39. Bernard, D.; Martinez-Leal, J. F.; Rizzo, S.; Martinez, D.; Hudson, D.; Visakorpi, T.; Peters, G.; Carnero, A.; Beach, D.; Gil, J. CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus Oncogene 2005, 24, 5543-5551
40. Yap, K. L.; Li, S.; Muñoz-Cabello, A. M.; Raguz, S.; Zeng, L.; Mujtaba, S.; Gil, J.; Walsh, M. J.; Zhou, M.-M. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by Polycomb CBX7 in transcriptional silencing of INK4a Mol. Cell 2010, 38, 662-674
41. NCT01897571 information available on http://www.clinicaltrials.gov.
42. van den Boom, V.; Rozenveld-Geugien, M.; Bonardi, F.; Malanga, D.; van Gosliga, D.; Heijink, A. M.; Viglietto, G.; Morrone, G.; Fusetti, F.; Vellenga, E.; Schuringa, J. J. Non-redundant and locus-specific gene repression functions of PRC1 paralog family members in human hematopoietic stem/progenitor cells Blood 2013, 121, 2452-2461
43. Scott, C. L.; Gil, J.; Hernando, E.; Teruya-Feldstein, J.; Narita, M.; Martinez, D.; Visakorpi, T.; Mu, D.; Cordon-Cardo, C.; Peters, G.; Beach, D.; Lowe, S. W. Role of the chromobox protein CBX7 in lymphomagenesis Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 5389-5394
44. Shinjo, K.; Yamashita, Y.; Yamamoto, E.; Akatsuka, S.; Uno, N.; Kamiya, A.; Niimi, K.; Sakaguchi, Y.; Nagasaka, T.; Takahashi, T.; Shibata, K.; Kajiyama, H.; Kikkawa, F.; Toyokuni, S. Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL-induced apoptotic pathway regulation. Int. J. Cancer [Online early access]. DOI: 10.1002/ijc.28692. Published Online: Jan 10, 2014.
45. Wyatt, A.; Collins, C. Vancouver Prostate Centre, personal communication.
46. Klauke, K.; Radulovic, V.; Broekhuis, M.; Weersing, E.; Zwart, E.; Olthof, S.; Ritsema, M.; Bruggeman, S.; Wu, X.; Helin, K.; Bystrykh, L.; de Haan, G. Polycomb Cbx family members mediate the balance between haematopoietic stem cell self-renewal and differentiation Nat. Cell Biol. 2013, 15, 353-362
47. Perry, A. S. Prostate cancer epigenomics J. Urol. 2013, 189, 10-11
48. Pallante, P.; Terracciano, L.; Carafa, V.; Schneider, S.; Zlobec, I.; Lugli, A.; Bianco, M.; Ferraro, A.; Sacchetti, S.; Troncone, G.; Fusco, A.; Tornillo, L the loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients Eur. J. Cancer 2010, 46, 2304-2313
49. Pallante, P.; Federico, A.; Berlingieri, M. T.; Bianco, M.; Ferraro, A.; Forzati, F.; Iaccarino, A.; Russo, M.; Pierantoni, G. M.; Leone, V.; Sacchetti, S.; Troncone, G.; Santoro, M.; Fusco, A. Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer Cancer Res. 2008, 68, 6770-6778
50. Federico, A.; Pallante, P.; Bianco, M.; Ferraro, A.; Esposito, F.; Monti, M.; Cozzolino, M.; Keller, S.; Fedele, M.; Leone, V.; Troncone, G.; Chiariotti, L.; Pucci, P.; Fusco, A. Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein Cancer Res. 2009, 69, 7079-7087
51. Forzati, F.; Federico, A.; Pallante, P.; Abbate, A.; Esposito, F.; Malapelle, U.; Sepe, R.; Palma, G.; Troncone, G.; Scarfo, M.; Arra, C.; Fedele, M.; Fusco, A. CBX7 is a tumor suppressor in mice and humans J. Clin. Invest. 2012, 122, 612-623
52. Klauke, K.; Radulović, V.; Broekhuis, M.; Weersing, E.; Zwart, E.; Olthof, S.; Ritsema, M.; Bruggeman, S.; Wu, X.; Helin, K.; Bystrykh, L.; de Haan, G. Polycomb Cbx family members mediate the balance between haematopoietic stem cell self-renewal and differentiation Nat. Cell Biol. 2013, 15, 353-362
53. qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. http://pubchem.ncbi.nlm.nih.gov/ assay/assay.cgi?aid=488953.
54. Huang, X. Fluorescence polarization competition assay: the range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand J. Biomol. Screening 2003, 8, 34-38